altropane Report issue

Small molecule Experimental
AACT DrugBank Drug Central MeSH PubChem

Active Ingredient History

NOW
  • Now
Altropane is a phenyltropane derivative which acts as a potent dopamine reuptake inhibitor and long-acting stimulant drug. It has mainly been used as the 125I radiolabelled form for mapping the distribution of dopamine transporters in the brain, and consequently this has led to its development as a potential diagnostic tool for early detection of Parkinson's disease. It is also being investigated for potential use in the diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).   Wikipedia

Chemistry

  • SMILES: COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@@H]2CC[C@H]1N2C/C=C/I
  • InChIKey: GTQLIPQFXVKRKJ-UNSMHXHVSA-N
  • Mol. Mass: 429.27
  • ALogP: 3.88
  • ChEMBL Molecule:
    altropane  
More Chemistry

Pharmacology

Alternative names

2-carbomethoxy-3-(4-fluorophenyl)-n-(1-iodoprop-1-en-3-yl)nortropane | altropane | iacft | n-iodoallyl-2-carbomethoxy-3-(4-fluorophenyl)tropane

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue